Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 133
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Contemp Oncol (Pozn) ; 28(1): 75-83, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38800535

RESUMEN

Introduction: This study aimed to evaluate the impact of tumour-infiltrating lymphocytes (TILs) on the expression of immune-related genes and prognosis in single hormone receptor-positive breast cancer. Material and methods: Tumour-infiltrating lymphocytes were analysed according to the guidelines of the International TILs Working Group in a cohort of 206 patients with single hormone receptor-positive breast cancer. Of these, 44.7% were classified as ER+/PgR-/HER2-, 18.4% as ER+/PgR-/HER2+, 26.2% as ER-/PgR+/HER2-, and 10.7% as ER-/PgR+/HER2+. Moreover, in 52 samples the analysis of gene expression profiling was performed using nCounter technology. Results: Most cases (74.3%) showed at least 1% of stromal TILs, with a median of 4%, mean of 16.3%, and interquartile range of 0-20%. ER-/PgR+ tumours displayed significantly higher TILs density than ER+/PgR- cases (p < 0.001, Wilcoxon test), regardless of HER2 status. The abundance of TILs was positively associated with ER-/PgR+ phenotype, higher Ki-67, and higher grade, but not with age, tumour size, or regional and distant metastases at diagnosis. Additionally, in ER+/PgR- subgroup higher TILs were associated with HER2-positive status. Stromal TILs > 5% were associated with better survival in the whole group, but this effect was less prominent in ER-/PgR+ patients. We identified 50 differentially expressed genes (DEGs) between single hormone receptor-positive breast tumours with high and low TILs, including 39 up-regulated and 11 down-regulated genes in the high TILs group. Conclusions: The up-regulated expression of immune-related genes was consistent also among separately analysed single hormone receptor-positive groups (ER+/PgR- and ER-/PgR+).

2.
Int J Cancer ; 153(5): 1003-1015, 2023 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-37338006

RESUMEN

High-grade gliomas are aggressive, deadly primary brain tumors. Median survival of patients with glioblastoma (GBM, WHO grade 4) is 14 months and <10% of patients survive 2 years. Despite improved surgical strategies and forceful radiotherapy and chemotherapy, the prognosis of GBM patients is poor and did not improve over decades. We performed targeted next-generation sequencing with a custom panel of 664 cancer- and epigenetics-related genes, and searched for somatic and germline variants in 180 gliomas of different WHO grades. Herein, we focus on 135 GBM IDH-wild type samples. In parallel, mRNA sequencing was accomplished to detect transcriptomic abnormalities. We present the genomic alterations in high-grade gliomas and the associated transcriptomic patterns. Computational analyses and biochemical assays showed the influence of TOP2A variants on enzyme activities. In 4/135 IDH-wild type GBMs we found a novel, recurrent mutation in the TOP2A gene encoding topoisomerase 2A (allele frequency [AF] = 0.03, 4/135 samples). Biochemical assays with recombinant, wild type (WT) and variant proteins demonstrated stronger DNA binding and relaxation activity of the variant protein. GBM patients carrying the altered TOP2A had shorter overall survival (median OS 150 vs 500 days, P = .0018). In the GBMs with the TOP2A variant we found transcriptomic alterations consistent with splicing dysregulation. luA novel, recurrent TOP2A mutation, which was found exclusively in four GBMs, results in the TOP2A E948Q variant with altered DNA binding and relaxation activities. The deleterious TOP2A mutation resulting in transcription deregulation in GBMs may contribute to disease pathology.


Asunto(s)
Neoplasias Encefálicas , Glioblastoma , Glioma , Humanos , Glioblastoma/patología , Neoplasias Encefálicas/metabolismo , Glioma/genética , Pronóstico , ADN , Isocitrato Deshidrogenasa/genética , Mutación
3.
Exp Mol Pathol ; 130: 104856, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36791903

RESUMEN

BACKGROUND: The mRNA splicing is regulated on multiple levels, resulting in the proper distribution of genes' transcripts in each cell and maintaining cell homeostasis. At the same time, the expression of alternative transcripts can change in response to underlying genetic variants, often missed during routine diagnostics. AIM: The main aim of this study was to define the frequency of aberrant splicing in BRCA1 and BRCA2 genes in blood RNA extracted from ovarian cancer patients who were previously found negative for the presence of pathogenic alterations in the 25 most commonly analysed ovarian cancer genes, including BRCA1 and BRCA2. MATERIAL AND METHODS: Frequency and spectrum of splicing alterations in BRCA1 and BRCA2 genes were analysed in blood RNA from 101 ovarian cancer patients and healthy controls (80 healthy women) using PCR followed by gel electrophoresis and Sanger sequencing. The expression of splicing events was examined using RT-qPCR. RESULTS: We did not identify any novel, potentially pathogenic splicing alterations. Nevertheless, we detected six naturally occurring transcripts, named BRCA1ΔE9-10, BRCA1ΔE11, BRCA1ΔE11q, and BRCA2ΔE3, BRCA2ΔE12 and BRCA2ΔE17-18 of which three (BRCA1ΔE11q, BRCA1ΔE11 and BRCA2ΔE3) were significantly higher expressed in the ovarian cancer cohort than in healthy controls (p ≤ 0.0001). CONCLUSIONS: This observation indicates that the upregulation of selected naturally occurring transcripts can be stimulated by non-genetic mechanisms and be a potential systemic response to disease progression and/or treatment. However, this hypothesis requires further examination.


Asunto(s)
Neoplasias de la Mama , Neoplasias Ováricas , Humanos , Femenino , Genes BRCA2 , Empalme Alternativo/genética , Mutación , Proteína BRCA2/genética , Proteína BRCA1/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Predisposición Genética a la Enfermedad/genética , ARN , Neoplasias de la Mama/genética
4.
Pol J Pathol ; 74(1): 1-11, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37306347

RESUMEN

Neuropathological central nervous system (CNS) post-mortem examination is a highly specialistic element of the autopsy procedure with methodological specificity. Herein we propose updated recommendations for CNS autopsy for pathologists and neuropathologists. The protocol includes the compendium of neuroanatomy with current nomenclature, consecutive steps of gross examination, as well as appropriate sampling algorithms in different clinical and pathological settings. The significance of pathoclinical cooperation in differential diagnosis is exposed. We believe it is essential to create and promote the guidelines to improve the quality of CNS post-mortem examination at the national level.


Asunto(s)
Encéfalo , Neuropatología , Humanos , Autopsia , Polonia , Médula Espinal
5.
Mod Pathol ; 35(11): 1609-1617, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35978013

RESUMEN

Sinonasal mucosal melanoma is a rare tumor arising within the nasal cavity, paranasal sinuses, or nasopharynx (sinonasal tract). This study evaluated 90 cases diagnosed in 29 males and 61 females with median age 68 years. Most tumors involved the nasal cavity and had an epithelioid morphology. Spectrum of research techniques used in this analysis includes targeted-DNA and -RNA next-generation sequencing, Sanger sequencing, fluorescence in situ hybridization and immunohistochemistry. Sinonasal melanomas were commonly driven by RAS (38/90, 42%), especially NRAS (n = 36) mutations and rarely (4/90, 4%) displayed BRAF pathogenic variants. BRAF/RAS mutants were more frequent among paranasal sinuses (10/14, 71%) than nasal (26/64, 41%) tumors. BRAF/RAS-wild type tumors occasionally harbored alterations of the key components and regulators of Ras-MAPK signaling pathway: NF1 mutations (1/17, 6%) or NF1 locus deletions (1/25, 4%), SPRED1 (3/25, 12%), PIK3CA (3/50, 6%), PTEN (4/50, 8%) and mTOR (1/50, 2%) mutations. These mutations often occurred in a mutually exclusive manner. In several tumors some of which were NRAS mutants, TP53 was deleted (6/48, 13%) and/or mutated (5/90, 6%). Variable nuclear accumulation of TP53, mirrored by elevated nuclear MDM2 expression was seen in >50% of cases. Furthermore, sinonasal melanomas (n = 7) including RAS/BRAF-wild type tumors (n = 5) harbored alterations of the key components and regulators of canonical WNT-pathway: APC (4/90, 4%), CTNNB1 (3/90, 3%) and AMER1 (1/90, 1%). Both, TERT promoter mutations (5/53, 9%) and fusions (2/40, 5%) were identified. The latter occurred in BRAF/RAS-wild type tumors. No oncogenic fusion gene transcripts previously reported in cutaneous melanomas were detected. Eight tumors including 7 BRAF/RAS-wild type cases expressed ADCK4::NUMBL cis-fusion transcripts. In summary, this study documented mutational activation of NRAS and other key components and regulators of Ras-MAPK signaling pathway such as SPRED1 in a majority of sinonasal melanomas.


Asunto(s)
Melanoma , Neoplasias de los Senos Paranasales , Senos Paranasales , Masculino , Femenino , Humanos , Anciano , Proteínas Proto-Oncogénicas B-raf/genética , Hibridación Fluorescente in Situ , Melanoma/genética , Melanoma/patología , Neoplasias de los Senos Paranasales/genética , Neoplasias de los Senos Paranasales/patología , Mutación , Transducción de Señal , Senos Paranasales/patología , Fosfatidilinositol 3-Quinasa Clase I/genética , Serina-Treonina Quinasas TOR/genética , ARN , Biología Molecular , Análisis Mutacional de ADN
6.
Neurol Neurochir Pol ; 56(2): 118-130, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34913473

RESUMEN

INTRODUCTION: Neuropathological brain and spinal cord post mortem examination is a distinct procedure that still plays an important role in modern medicine. In front of increasing amounts of clinical and genetic data, together with important developments in the field of neuroimaging, the Polish Association of Neuropathologists have updated their recommendations regarding central nervous system (CNS) examination. These guidelines are aimed at neuropathologists, pathologists and clinicians. AIM OF THE STUDY: Presentation of the outlined recommendations as their goal is to improve the quality, informativity, and cost effectiveness of CNS post mortem examinations. A comprehensive study of the literature was conducted to provide a clinical background of neuropathological autopsy. There are numerous open questions in neuroscience, and new strategies are required to foster research in CNS diseases. These include the challenge of organizing brain banks tasked with managing and protecting detailed multidisciplinary information about their resources. Complex neuropathological analyses of post mortem series are also important to assess the effectiveness of diagnostics and therapy, identify environmental impact on the development of neurological disorders, and improve public health policy. The recommendations outline the need for collaboration between multiple specialists to establish the proper diagnosis and to broaden knowledge of neurological disorders.


Asunto(s)
Enfermedades del Sistema Nervioso Central , Neuropatología , Autopsia/métodos , Encéfalo/patología , Enfermedades del Sistema Nervioso Central/patología , Humanos , Neuroimagen
7.
Neurol Neurochir Pol ; 55(5): 450-461, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34379320

RESUMEN

INTRODUCTION: Due to the widespread use of magnetic resonance imaging (MRI) in neurological diagnostics, the number of patients detected as having cerebral microbleeds (CMBs) continues to increase. However, their clinical impact still remains controversial, especially the question of whether CMBs significantly increase the risk of life-threatening intracerebral haemorrhage (ICH) in patients undergoing intravenous thrombolysis (IVT) or endovascular thrombectomy (EVT), or in patients on anticoagulant therapy or statins. STATE OF THE ART: The term 'CMB' is a radiological concept that aims to illustrate microscopic pathology of perivascular hemosiderin deposits corresponding most probably to small foci of past bleeding. MRI images in sequence T2*-GRE and susceptibility-weighted imaging (SWI) are used for a diagnosis of a CMB. This review summarises the current knowledge regarding the definition, prevalence, genetics, risk factors, radiological diagnosis and differential diagnosis of a CMB. We discuss its role as an indicator of future ischaemic or haemorrhagic events in high risk patients or those on antiplatelet or anticoagulant therapy, and its prognostic value for reperfusion strategies and for the development of dementia. FUTURE DIRECTION: The place of CMBs in current guidelines is explored herein. It must be emphasised that the recommendations relating to CMBs are expert opinions. Therefore, at the end of this review, we pose a number of questions that future clinical trials should answer.


Asunto(s)
Hemorragia Cerebral , Accidente Cerebrovascular , Hemorragia Cerebral/diagnóstico por imagen , Humanos , Imagen por Resonancia Magnética , Radiografía , Factores de Riesgo , Accidente Cerebrovascular/diagnóstico por imagen , Trombectomía
8.
Pathobiology ; 87(2): 87-99, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32045912

RESUMEN

The tumor microenvironment (TME) plays an essential role in the development and progression of neoplasms. TME consists of the extracellular matrix and numerous specialized cells interacting with cancer cells by paracrine and autocrine mechanisms. Tumor axonogenesis and neoneurogenesis constitute a developing area of investigation. Prostate cancer (PC) is one of the most common malignancies in men worldwide. During the past years, more and more studies have shown that mechanisms leading to the development of PC are not confined only to the epithelial cancer cell, but also involve the tumor stroma. Different nerve types and neurotransmitters present within the TME are thought to be important factors in PC biology. Moreover, perineural invasion, which is a common way of PC spreading, in parallel creates the neural niche for malignant cells. Cancer neurobiology seems to have become a new discipline to explore the contribution of neoplastic cell interactions with the nervous system and the neural TME component, also to search for potential therapeutic targets in malignant tumors such as PC.


Asunto(s)
Sistema Nervioso/patología , Neoplasias de la Próstata/patología , Microambiente Tumoral , Animales , Progresión de la Enfermedad , Humanos , Masculino , Ratones , Neoplasias de la Próstata/terapia , Transducción de Señal
9.
Biomarkers ; 24(6): 538-548, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30995126

RESUMEN

Objective: The study was to assess whether tumour expressions of hypoxia-inducible factor (HIF)-1α, glucose transporter (GLUT)-1, carbonic anhydrase (CA) IX and vascular endothelial growth factor (VEGF) predict response to neo-adjuvant chemotherapy (naCHT) in children with inoperable rhabdomyosarcoma (RMS). Methods: Immunohistochemical expressions of hypoxia markers were determined semi-quantitatively in tumour tissue microarray of 46 patients with embryonal RMS (RME) and 20 with alveolar (RMA), treated with CWS protocols (1992-2013). Results: In paediatric RME, response to naCHT was influenced significantly by tumour expression of CA IX and GLUT-1. Patients with RMA with low expressions of analysed markers responded well to naCHT, while all poor-responders expressed highly hypoxia markers. Only 5.88% of RMA and 11.11% of RME tumours did not express any of the proteins. In both RME and RMA subgroups, most poor-responders demonstrated simultaneous high expression of ≥3 markers, while most patients expressing ≤2 markers responded well to naCHT. In the whole cohort, co-expression of ≥3 markers, was the only independent factor predicting poor-response to chemotherapy (odds ratio 14.706; 95% CI 1.72-125.75; p = 0.014). Conclusions: Immunohistochemical expression pattern of four endogenous markers of hypoxia, in tumour tissue at diagnosis, emerges as a promising tool to predict response to naCHT in children with inoperable RMS.


Asunto(s)
Antígenos de Neoplasias/genética , Biomarcadores de Tumor/genética , Anhidrasa Carbónica IX/genética , Transportador de Glucosa de Tipo 1/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Neoplasias de los Músculos/tratamiento farmacológico , Rabdomiosarcoma Alveolar/tratamiento farmacológico , Rabdomiosarcoma Embrionario/tratamiento farmacológico , Factor A de Crecimiento Endotelial Vascular/genética , Adolescente , Antígenos de Neoplasias/metabolismo , Biomarcadores de Tumor/metabolismo , Biopsia , Anhidrasa Carbónica IX/metabolismo , Carboplatino/uso terapéutico , Quimioterapia Adyuvante/métodos , Niño , Preescolar , Dactinomicina/uso terapéutico , Epirrubicina/uso terapéutico , Femenino , Expresión Génica , Transportador de Glucosa de Tipo 1/metabolismo , Humanos , Hipoxia/diagnóstico , Hipoxia/tratamiento farmacológico , Hipoxia/genética , Hipoxia/mortalidad , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Ifosfamida/uso terapéutico , Lactante , Recién Nacido , Masculino , Neoplasias de los Músculos/diagnóstico , Neoplasias de los Músculos/genética , Neoplasias de los Músculos/mortalidad , Terapia Neoadyuvante/métodos , Pronóstico , Estudios Prospectivos , Rabdomiosarcoma Alveolar/diagnóstico , Rabdomiosarcoma Alveolar/genética , Rabdomiosarcoma Alveolar/mortalidad , Rabdomiosarcoma Embrionario/diagnóstico , Rabdomiosarcoma Embrionario/genética , Rabdomiosarcoma Embrionario/mortalidad , Análisis de Supervivencia , Resultado del Tratamiento , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vincristina/uso terapéutico
10.
Clin Neuropathol ; 38(4): 174-179, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30900986

RESUMEN

The wide scope of neuropathology is also connected to different systemic pathology findings. Neuroectodermal-type female genital tract lesions are not frequent. This article presents a short review of such entities in gynecological pathology and reports on two rare cases. The first described lesion is an endometrial glial polyp in a young woman. The second is a mature cystic teratoma accompanied by a peritoneal gliomatosis in an adolescent girl. Both presented entities posed diagnostic difficulties from the clinical and pathological perspective. They demanded careful sampling, immunophenotyping, as well as neuropathological consultation.


Asunto(s)
Glioma/patología , Neuroglía/patología , Neuropatología , Teratoma/patología , Adolescente , Biopsia/métodos , Femenino , Glioma/diagnóstico , Humanos , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/patología , Neuropatología/métodos , Teratoma/diagnóstico , Adulto Joven
11.
Pol J Pathol ; 70(1): 33-41, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31556549

RESUMEN

We present an analysis of two first historically documented limb body wall complex (LBWC) cases and our own contemporary perinatal autopsy series of this rare complex. So far it was supposed that the first case of this complex was reported in 1685 by Paul Portal. Studying the Joachim Oelhaf's autopsy report from 1613 with attached engraving showing the neonate with multiple birth defects led our research team to a conclusion that it was genuinely the first description of LBWC in the medical literature so far. We compared the Oelhaf's case from 1613 and the Portal's autopsy report from 1685 with our series of LBWC cases dissected in the Medical University of Gdansk between 1999 and 2011. Reviewing 1100 autopsy reports performed we encountered 9 cases of this unique complex. The analysis was supported by the literature review.


Asunto(s)
Anomalías Múltiples/historia , Deformidades Congénitas de las Extremidades/historia , Autopsia , Femenino , Historia del Siglo XVII , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Recién Nacido , Embarazo
12.
BMC Gastroenterol ; 18(1): 10, 2018 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-29334905

RESUMEN

BACKGROUND: Different clinical behaviour influences the importance of differentiating focal nodular hyperplasia (FNH) from other focal liver lesions (FLLs). The aim of this study was to compare the efficacy of contrast-enhanced CT and MRI in the diagnosis of FNH. METHODS: 157 patients with equivocal FLLs detected in ultrasonography subsequently underwent multi-phase CT and MRI with the use of hepatotropic contrast agent (Gd-BOPTA) in a 1.5 T scanner. Examinations were evaluated by three independent readers. Diagnostic efficacy of different radiological signs of FNH in both CT and MRI was compared and AFROC analysis was performed. RESULTS: 4 hepatocellular adenomas, 95 hepatocellular carcinomas, 98 hemangiomas, 138 metastases and 45 FNHs were diagnosed. In both CT and MRI the radiological sign of the highest accuracy was the presence of the central scar within FNH (0.93 and 0.96 relatively). The sum of two radiological signs in MRI: homogeneous enhancement in hepatic arterial phase (HAP) and enhancing lesion in hepatobiliary phase (HBP) was characterized with high values of sensitivity (0.89), specificity (0.97), PPV (0.82), NPV (0.98) and accuracy (0.96). After inclusion of clinical data into analysis the best discriminating feature in MRI was the presence of enhancing lesion in HBP in patients without cirrhosis. In this regard, efficacy parameters increased to 1.00, 0.99, 0.94, 1.00 and 0.99 accordingly. The area under the curve in AFROC analysis of MRI performance was significantly larger than of CT (p = 0.0145). CONCLUSION: Gd-BOPTA-enhanced MRI is a more effective method in the differential diagnosis of FNH than multi-phase CT.


Asunto(s)
Hiperplasia Nodular Focal/diagnóstico por imagen , Imagen por Resonancia Magnética , Tomografía Computarizada Multidetector , Adenoma de Células Hepáticas/diagnóstico por imagen , Adulto , Carcinoma Hepatocelular/diagnóstico por imagen , Medios de Contraste , Diagnóstico Diferencial , Femenino , Gadolinio DTPA , Hemangioma/diagnóstico por imagen , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/secundario , Imagen por Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
13.
Pol J Pathol ; 69(2): 118-127, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30351858

RESUMEN

The second part of the comprehensive work concerning pathology museums and collections presents their history since the 19th century. The evolution and specialisation of museums, depending on the attitude of their creators and geographic localization, have been analysed. The changing aspects of obtaining the exhibits and how they were preserved, presented, and stored are also a part of this work. The methods of human organ fixation reached excellence in the 19th century, but the rarity of some pathologies urged the scientists to recreate them artificially in models for didactic purposes. In the 19th and 20th centuries one could observe the flourishing development with a plateau and then decline from the second part of the 20th century to the reorientation of the museums that took place in Europe and North America. The history of anatomopathological museums is connected with ethical problems related to acquisition of exhibits in previous centuries and especially during World War II. The changing purpose of the collections, as well as their unclear future and the impact on the visitors, are evident. For the last 50 years, many museums have been closing completely, but some collections have been digitalised and are still in permanent use. The uniqueness of old specimens with certain diseases, often long gone and not observed anymore, makes them important in many aspects nowadays. Pathology museums are themselves relics of the past, being at the same time tangible proof of ways of development in medicine, but also a way of preservation of human knowledge in a special type of relation with the human body.


Asunto(s)
Museos/historia , Patología/historia , Europa (Continente) , Historia del Siglo XIX , Historia del Siglo XX , Humanos
14.
Am J Pathol ; 186(11): 3040-3053, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27743558

RESUMEN

Neuroblastoma (NB) is a pediatric malignant neoplasm of sympathoadrenal origin. Challenges in its management include stratification of this heterogeneous disease and a lack of both adequate treatments for high-risk patients and noninvasive biomarkers of disease progression. Our previous studies have identified neuropeptide Y (NPY), a sympathetic neurotransmitter expressed in NB, as a potential therapeutic target for these tumors by virtue of its Y5 receptor (Y5R)-mediated chemoresistance and Y2 receptor (Y2R)-mediated proliferative and angiogenic activities. The goal of this study was to determine the clinical relevance and utility of these findings. Expression of NPY and its receptors was evaluated in corresponding samples of tumor RNA, tissues, and sera from 87 patients with neuroblastic tumors and in tumor tissues from the TH-MYCN NB mouse model. Elevated serum NPY levels correlated with an adverse clinical presentation, poor survival, metastasis, and relapse, whereas strong Y5R immunoreactivity was a marker of angioinvasive tumor cells. In NB tissues from TH-MYCN mice, high immunoreactivity of both NPY and Y5R marked angioinvasive NB cells. Y2R was uniformly expressed in undifferentiated tumor cells, which supports its previously reported role in NB cell proliferation. Our findings validate NPY as a therapeutic target for advanced NB and implicate the NPY/Y5R axis in disease dissemination. The correlation between elevated systemic NPY and NB progression identifies serum NPY as a novel NB biomarker.


Asunto(s)
Neuroblastoma/metabolismo , Neuropéptido Y/metabolismo , Adolescente , Animales , Biomarcadores/metabolismo , Proliferación Celular , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Ratones , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/patología , Neuropéptido Y/genética , Receptores de Neuropéptido Y/genética , Receptores de Neuropéptido Y/metabolismo
15.
Future Oncol ; 13(12): 1069-1079, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28095720

RESUMEN

AIM: This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with 90Y-[DOTA0, D-Phe1, Tyr3]-octreotate. PATIENTS & METHODS: CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of 90Y-[DOTA0, D-Phe1, Tyr3]-octreotate. The primary end point was overall survival. RESULTS: Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression. CONCLUSION: Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.


Asunto(s)
Biomarcadores de Tumor , Cromogranina A/sangre , Neoplasias Intestinales/sangre , Neoplasias Intestinales/mortalidad , Tumores Neuroendocrinos/sangre , Tumores Neuroendocrinos/mortalidad , Neoplasias Pancreáticas/sangre , Neoplasias Pancreáticas/mortalidad , Neoplasias Gástricas/sangre , Neoplasias Gástricas/mortalidad , Terapia Combinada , Progresión de la Enfermedad , Femenino , Humanos , Neoplasias Intestinales/diagnóstico , Neoplasias Intestinales/terapia , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Metástasis de la Neoplasia , Estadificación de Neoplasias , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/terapia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/terapia , Pronóstico , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/terapia , Resultado del Tratamiento
16.
Contemp Oncol (Pozn) ; 21(4): 279-284, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29416433

RESUMEN

AIM OF THE STUDY: Examination of copy number changes in a group of intracranial germ cell tumors (GCTs) with particular focus on putative aberrations of the main genes coding SHh pathway proteins. MATERIAL AND METHODS: The study was performed on DNA isolated from fresh-frozen tumor tissue samples from eight GCTs, including six intracranial GCTs. The intracranial group consisted of three germinomas, two mature teratomas and one mixed germ cell tumor. Comparative genomic profiling analysis was carried out using microarray-CGH method (Cytosure ISCA UPD 4×180k, OGT). The results were analyzed with Feature Extraction (Agilent Technologies) and Nexus Copy Number (BioDiscovery) softwares. RESULTS AND CONCLUSIONS: Chromosomal aberrations were found in two intracranial germinomas. These tumors were characterized by complex genomic profiles encompassing chromosomes 7, 8, 9, 10, 11, 12, 16, 17 and 19. Common findings were gain at 12p13.33p11.1 of 35 Mbp and gain at 17q11.1q25.3 of 55 Mbp. In one tumor, also SHh (7q36.3), SMO (7q32.1) and GLI3 (7p14.1) copy gains occurred together with 9q21.11q34.3 loss, including PTCH1, all being elements of SHh signaling pathway. Moreover, both tumors showed various copy gain of genes being ligands, regulators, receptors or target genes of SHh (MTSS1; PRKACA and FKBP8) as well as gain of genes of SHh coopting WNT pathway (WNT3, WNT5B, WNT9B in both tumors; WNT16, WNT2 in pineal lesion). Further studies on larger group are needed to characterize SHh-related gene alterations in intracranial GCTs and for searching genotype-phenotype relations.

17.
Immunol Invest ; 45(8): 787-796, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27759462

RESUMEN

BACKGROUND/AIMS: To determine the proportion of T-regulatory cells (CD4+CD25highFOXP3+ cells) in peripheral blood and the number of FOXP3+ cells in intestinal mucosa of children with inflammatory bowel disease (IBD), and to verify whether these parameters correlate with the activity of the disease. MATERIAL AND METHODS: 24 patients newly diagnosed for IBD were included in the study: ulcerative colitis (UC; n = 13) and Crohn's disease (CD; n = 11). Seventeen healthy controls (HC) and 16 patients with irritable bowel syndrome (IBS) served as a control group for peripheral and intestinal Tregs assessment, respectively. The disease activity was assessed by Pediatric Ulcerative Colitis Activity Index (PUCAI) and Pediatric Crohn's Disease Activity Index (PCDAI). Quantification of regulatory T cells of CD4+CD25highFOXP3+ phenotype in peripheral blood was based on three-color flow cytometry. Mucosal Tregs represented by FOXP3+ cells were evaluated using immunohistochemistry. RESULTS: Median proportion of CD4+CD25highFOXP3+ cells among CD4+ T cells in peripheral blood (5.1%, range 1.7-84% vs. 4.3%, range 2-8.1%, p = 0.023) and median number of intestinal FOXP3+ cells (115.33 per high-power field, hpf, range 39.33-375.67 vs. 10.16 per hpf, range 5-30, p = 0.0001) were significantly higher in children with IBD than in the controls. The proportion of circulating Tregs and the number of intestinal FOXP3+ cells did not correlate with clinical activity of the disease, as well as with endoscopic and histopathologic scoring. No significant correlation was found between the percentage of peripheral CD4+CD25highFOXP3+ cells and the number of intestinal FOXP3+cells. CONCLUSIONS: Children with IBD likely do not present with a quantitative deficiency of circulating and intestinal Tregs at the moment of diagnosis.

18.
Pediatr Int ; 58(10): 1066-1068, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27592612

RESUMEN

Although childhood rhabdomyosarcoma typically metastasizes to lungs, various processes may mimic metastatic etiology. Described herein is the case of an 8½-year-old boy with orbital embryonal rhabdomyosarcoma (RME) in whom three small foci were detected within both lungs on computed tomography. The lesion number and size, however, did not fulfil the Cooperative Weichteilsarkom Study Group 2006 protocol criteria for lung metastasis. Chemotherapy for localized RME produced primary tumor regression and vanishing of the left lung lesion. Two lesions in the right lung remained unchanged. On thoracoscopy multiple minute nodules disseminated in both lungs were detected. Histopathology excluded RME spread but indicated anthracosis in the lung parenchyma and intrapulmonary lymph nodes. Heavy smoking by parents and previous home furnace combustion appeared to be predisposing factors. Uncommon non-malignant intrapulmonary diseases, including anthracosis, should be considered when staging pediatric cancer.


Asunto(s)
Antracosis/complicaciones , Neoplasias Pulmonares/diagnóstico , Pulmón/diagnóstico por imagen , Neoplasias Orbitales/complicaciones , Rabdomiosarcoma Embrionario/complicaciones , Antracosis/diagnóstico , Biopsia , Niño , Diagnóstico Diferencial , Humanos , Imagen por Resonancia Magnética , Masculino , Neoplasias Orbitales/diagnóstico , Rabdomiosarcoma Embrionario/diagnóstico , Tomografía Computarizada por Rayos X
19.
Pol J Pathol ; 67(3): 207-215, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-28155968

RESUMEN

We present a short history of anatomopathological museums in Europe. In the first part we provide an insight into the beginnings from the Renaissance until the middle of the 19th century. We assess forms of acquisition and exhibition of the specimens concerning the steps of medicine and pathology development. The prototypes were "curiosities of nature" collections starting in the 15th century. The next milestone collections focusing on the human body were those of Frederik Ruysch in the Netherlands (17th century). In the 18th century teachers in surgical and anatomical schools realized the educational power of such collections. Anatomopathology as a separate medical discipline was developing in parallel. At that time museums such as the one established by Honoré Fragonard in Paris, the Hunterian in Glasgow and Narrenturm in Vienna were created. At Polish universities in Cracow and Vilnius, such museums were beginning to emerge at the beginning of the 19th century. Anatomopathological collections became more popular, gathering specimens: osteological, dry and mummified, as well as wet - embedded in alcohol, formalin, and mysterious mixtures. They provide a wealth of important data for scientific, medical, historical and even ethical areas, as well as methods and concepts of conservation and even recreation of human body parts.


Asunto(s)
Museos/historia , Patología/historia , Europa (Continente) , Historia del Siglo XV , Historia del Siglo XVI , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos
20.
Cancer ; 121(5): 697-707, 2015 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-25387699

RESUMEN

BACKGROUND: Ewing sarcoma (ES) is driven by fusion of the Ewing sarcoma breakpoint region 1 gene (EWSR1) with an E26 transformation-specific (ETS) transcription factor (EWS-ETS), most often the Friend leukemia integration 1 transcription factor (FLI1). Neuropeptide Y (NPY) is an EWS-FLI1 transcriptional target; it is highly expressed in ES and exerts opposing effects, ranging from ES cell death to angiogenesis and cancer stem cell propagation. The functions of NPY are regulated by dipeptidyl peptidase IV (DPPIV), a hypoxia-inducible enzyme that cleaves the peptide and activates its growth-promoting actions. The objective of this study was to determine the clinically relevant functions of NPY by identifying the associations between patients' ES phenotype and their NPY concentrations and DPP activity. METHODS: NPY concentrations and DPP activity were measured in serum samples from 223 patients with localized ES and 9 patients with metastatic ES provided by the Children's Oncology Group. RESULTS: Serum NPY levels were elevated in ES patients compared with the levels in a healthy control group and an osteosarcoma patient population, and the elevated levels were independent of EWS-ETS translocation type. Significantly higher NPY concentrations were detected in patients with ES who had tumors of pelvic and bone origin. A similar trend was observed in patients with metastatic ES. There was no effect of NPY on survival in patients with localized ES. DPP activity in sera from patients with ES did not differ significantly from that in healthy controls and patients with osteosarcoma. However, high DPP levels were associated with improved survival. CONCLUSIONS: Systemic NPY levels are elevated in patients with ES, and these high levels are associated with unfavorable disease features. DPPIV in serum samples from patients with ES is derived from nontumor sources, and its high activity is correlated with improved survival.


Asunto(s)
Neoplasias Óseas/sangre , Dipeptidil Peptidasa 4/sangre , Neuropéptido Y/sangre , Proteínas de Fusión Oncogénica/genética , Proteína Proto-Oncogénica c-fli-1/genética , Proteína EWS de Unión a ARN/genética , Sarcoma de Ewing/sangre , Adolescente , Animales , Neoplasias Óseas/genética , Neoplasias Óseas/mortalidad , Línea Celular Tumoral , Niño , Dipeptidil Peptidasa 4/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Ratones , Ratones SCID , Trasplante de Neoplasias , Neuropéptido Y/genética , Neuropéptido Y/metabolismo , Osteosarcoma/sangre , Osteosarcoma/genética , ARN Mensajero/genética , Receptores de Neuropéptido Y/genética , Sarcoma de Ewing/genética , Sarcoma de Ewing/mortalidad , Trasplante Heterólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA